2009
Chapter 1 The Function, Proteolytic Processing, and Histopathology of Met in Cancer
Hanna JA, Bordeaux J, Rimm DL, Agarwal S. Chapter 1 The Function, Proteolytic Processing, and Histopathology of Met in Cancer. Advances In Cancer Research 2009, 103: 1-23. PMID: 19854350, DOI: 10.1016/s0065-230x(09)03001-2.Peer-Reviewed Original ResearchConceptsHepatocyte growth factorExpression of METLocalization of MetClinicopathological characteristicsMET receptor tyrosine kinaseTherapeutic targetCancer typesReceptor tyrosine kinasesCancer treatmentGrowth factorCancer cellsCell proliferationMetSProteolytic processingHistopathologyCancerTyrosine kinaseRecent studiesImproper regulationNuclear localizationAntibodies
2007
Definition of a direct extracellular interaction between Met and E‐cadherin
Reshetnikova G, Troyanovsky S, Rimm DL. Definition of a direct extracellular interaction between Met and E‐cadherin. Cell Biology International 2007, 31: 366-373. PMID: 17336101, DOI: 10.1016/j.cellbi.2007.01.022.Peer-Reviewed Original ResearchConceptsBT-549 cellsE-cadherinCadherin-dependent cell-cell contactsHT-29 cellsE-cadherin interactsHepatocyte growth factorCell-cell adhesionCell-cell contactCross-linking studiesDirect extracellular interactionTyrosine kinase receptor expressionExtracellular interactionsMolecular mechanismsExtracellular domainIntracellular compartmentsPhysical interactionCellular presentationFirst evidenceGrowth factorCellsBT-549HT-29ExpressionReceptor expressionMetS
2003
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Research 2003, 63: 1101-5. PMID: 12615728.Peer-Reviewed Original ResearchConceptsHepatocyte growth factor activator inhibitor-1Breast carcinomaSeries of proteasesNode-negative breast cancerHigh-level expressionNode-negative breast carcinomaHGF/MET pathwayIndependent prognostic valueBreast cancer progressionPoor patient outcomesTissue microarray analysisPathway componentsMicroarray analysisExtracellular domainActivator inhibitor-1Expression of HGFOverexpression of METMet receptorHepatocyte growth factorCancer progressionMatriptasePrognostic valueBreast markersPatient followPatient outcomes
1999
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma
Camp R, Rimm E, Rimm D. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86: 2259-2265. PMID: 10590366, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2259::aid-cncr13>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsAxillary lymph node negative breast carcinomaLymph node negative breast carcinomaExpression of METNode-negative breast carcinomaNegative breast carcinomaBreast carcinomaMET expressionMetastatic diseaseRelative riskNegative invasive ductal carcinomaLow Met expressionMET-negative patientsIndependent predictive valueIndependent prognostic markerUseful prognostic indicatorInvasive ductal carcinomaStandard immunoperoxidase techniqueHigh MET expressionHepatocyte growth factorActivation of METAxillary lymphNegative patientsPatient agePrognostic factorsAggressive disease
1998
Expression of c‐met is a strong independent prognostic factor in breast carcinoma
Ghoussoub R, Dillon D, D'Aquila T, Rimm E, Fearon E, Rimm D. Expression of c‐met is a strong independent prognostic factor in breast carcinoma. Cancer 1998, 82: 1513-1520. PMID: 9554529, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1513::aid-cncr13>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsBreast carcinomaIndependent predictorsStrong independent prognostic factorCox proportional hazards modelGrowth factorIndependent prognostic factorLymph node statusSubset of patientsInvasive ductal carcinomaUseful prognostic markerProportional hazards modelBreast tumor specimensHepatocyte growth factorNegative patientsPrognostic factorsAggressive diseaseDuctal carcinomaNode statusPrognostic valuePrognostic markerTumor specimensHazards modelPatientsPredictive valueSurvival rate